Clinical trials: Hepatitis C, completed
Hepatitis C
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
HCV002TV is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV) in chronically infected patients.
- Trial name
- NCT01094873
- Testing
- AdCh3NSmut, Ad6NSmut
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- ReiThera Srl
Hepatitis C
TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers
The purpose of this study is to evaluate the effect of TMC435 on the results of electrocardiograms (ECGs) in healthy volunteers. An electrocardiogram is an electric recording of the heart.
- Trial name
- NCT01269294
- Testing
- TMC435, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Hepatitis C, Chronic
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs
This project aims to evaluate two strategies of Hepatitis C virus (HCV) testing compared to standard of care among people who inject drugs at needle and syringe program (NSP) services in Australia, to see if it can improve the…
- Trial name
- TEMPO (NCT04014179)
- Testing
- Xpert HCV Viral Load Fingerstick, Aptima HCV Quant DX Assay
- Where
- 17 sites in Australia
- Volunteers
- 1,801 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Infection
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic…
- Trial name
- NCT02356562
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin
- Volunteers
- 29 people
- Sponsor
- AbbVie
Hepatitis C
CTS-1027 in Interferon-Naive Hepatitis C Patients
The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.
- Trial name
- NCT00925990
- Testing
- ribavirin, CTS-1027
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 70 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Chronic Hepatitis C
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the issues of improving host…
- Trial name
- Addwin (NCT01439776)
- Testing
- Vit D
- Where
- 13 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Hanyang University
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Characterization of Clonal B Cell Populations in HCV Infection
The purpose of this study is to investigate the mechanism of autoantibody production during chronic hepatitis C virus (HCV) infection. 10-50% of individuals with HCV have symptoms of mixed cryoglobulinemia (MC).
- Trial name
- NCT00435201
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks…
- Trial name
- NCT01701401
- Testing
- LDV/SOF, RBV
- Where
- 88 sites in United States, France and 5 more
- Volunteers
- 870 people
- Sponsor
- Gilead Sciences
Hepatitis C
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C. II.
- Trial name
- NCT00004804
- Testing
- interferon alfa
- Volunteers
- 57 people
- Sponsor
- National Center for Research Resources (NCRR)
Hepatitis C
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C is a blood borne virus that can seriously damage the liver. An estimated 50,000 Scots have been infected with Hepatitis C virus (HCV). The main driver for spread of HCV infection is intravenous drug use.
- Trial name
- ADVANCE (NCT03236506)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG
- Where
- 2 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University of Dundee
HIV, HTLV-1
Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa
Kinshasa, Democratic Republic of Congo (DRC), is where human immunodeficiency virus type 1 (HIV-1) appears to have most diversified.
- Conditions
- HIV, HTLV-1, Hepatitis C, Chronic
- Trial name
- NCT02439918
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks.
- Trial name
- CHAMPS (NCT02402218)
- Testing
- Usual care plus peer-mentors, Usual care plus incentives, Usual Care
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis C
Effect of Boceprevir on HCV-specific T Cell Responses
Analysis of HCV-specific T cell responses in patients treated with boceprevir to assess whether therapy can induce restoration of the T cell function and to what extent this recovery can be achieved
- Trial name
- Boce-Par (NCT01403181)
- Testing
- Boceprevir
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Chronic Hepatitis C Virus Infection
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to assess the safety, tolerability, pharmacokinetics and antiviral activity of ABT-333 (also known as dasabuvir) in treatment-naïve, hepatitis C virus (HCV)-infected participants.
- Trial name
- NCT00851890
- Testing
- ABT-333, Pegylated interferon, Ribavirin
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus…
- Trial name
- NCT01316237
- Testing
- GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
The purpose of this study is to describe the genetic diversity of Hepatitis C virus (HCV) NS3/4a protease and NS5A protein of HCV in participants with chronic disease naive-drug or previously failed to double therapy…
- Trial name
- MAPPING (NCT02597270)
- Where
- 6 sites in Brazil
- Volunteers
- 239 people
- Sponsor
- Janssen-Cilag Ltd.
Hepatitis C
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C.
- Trial name
- NCT00372983
- Testing
- NOV-205
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
HIV/AIDS, Hepatitis C
Study of HIV, HCV, APS and Phylogenetics for PWID
This study will determine whether assisted partner notification services (APS) can identify and link to care, the sexual and needle-sharing partners of HIV-infected and HIV/hepatitis C (HCV) co-infected persons who inject drugs…
- Trial name
- SHARP (NCT03447210)
- Testing
- Assisted Partner Services
- Where
- 3 sites in Kenya
- Volunteers
- 4,301 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.